| Today’s Big NewsNov 15, 2023 |
| By Annalee Armstrong Regeneron is pretty good at making antibodies. It’s kind of its thing. But while the industry has gone crazy for antibody-drug conjugates, the company has stayed out of the limelight. |
|
|
|
By Max Bayer Organon CEO Kevin Ali says that while it wasn't involved in the recent women's health initiative announced by the White House, it plans to be moving forward. |
By Annalee Armstrong Lenz Therapeutics is absorbing sickle-cell-focused Graphite Bio in a reverse merger that will see the combined company reemerge with a focus on vision loss and $225 million in cash on hand at close. |
Sponsored by Questex Fierce Biotech sits down with digital marketing leaders to discuss this year's most innovative topics at Fierce Biotech Summit and New Product Planning |
|
Reduce sequence artifacts that dampen variant calling sensitivity. Prepare highly complex libraries in under 1.5 hours, and minimize damage and loss with precious low-input and FFPE material. Learn more.
|
|
By Nick Paul Taylor Gilead’s Kite is paying Arcellx $285 million to inject a SparX into its pursuit of BCMA. In return for the outlay, $200 million of which is being invested in Arcellx, Kite has secured rights to an early-phase BCMA CAR-T candidate and expanded its existing midphase cell therapy collaboration to cover lymphomas. |
By Annalee Armstrong Mural Oncology, Alkermes’ cancer spinoff, has officially landed with $275 million in funding and a mission to develop an IL-2 candidate for solid tumors. |
By Nick Paul Taylor Atreca is handing out pink slips at a furious rate in a fight to survive, reducing its head count by 40% for the second time in three months in a bid to keep the lights on until strategic alternatives can be identified. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Angus Liu In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival. |
By Angus Liu An upcoming meeting of the FDA’s oncologic drugs advisory committee is slated to serve as a reminder for cancer drug developers that the agency is keeping a close eye on accelerated approvals. |
By Andrea Park Unfortunately for Vicarious Surgical, the robotic surgery system developer is ending the year the same way it began: with a round of layoffs. |
By Heather Landi Primary care player Forward unveiled this week what it has been quietly working on the past two years—self-serve CarePods that use artificial intelligence to screen and diagnose health conditions. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of "Podnosis," you'll hear from two journalists from the Fierce Healthcare team: Paige Minemyer, senior editor of Fierce Health Payer, and Dave Muoio, a staff writer for Fierce Healthcare. Together, they guide you through their key insights from the inaugural Fierce Health Payer Summit in Austin and dive into the latest earnings updates from the largest health plans and health systems. |
|
|---|
|
|
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
